My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 275

    1.

    Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.

    Lieschke GJ, Maher D, Cebon J, O'Connor M, Green M, Sheridan W, Boyd A, Rallings M, Bonnem E, Metcalf D, et al.

    Ann Intern Med. 1989 Mar 1;110(5):357-64.PMID: 2644886 [PubMed - indexed for MEDLINE]Related articles

    2.

    Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.

    Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, Bonnem E, Burgess AW, McGrath K, Fox RM, et al.

    Cancer Res. 1990 Feb 1;50(3):606-14.PMID: 2404573 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor.

    Vadhan-Raj S, Buescher S, LeMaistre A, Keating M, Walters R, Ventura C, Hittelman W, Broxmeyer HE, Gutterman JU.

    Blood. 1988 Jul;72(1):134-41.PMID: 3291976 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

    Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R.

    J Clin Oncol. 1989 Feb;7(2):159-67.PMID: 2644395 [PubMed - indexed for MEDLINE]Related articles

    5.

    Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.

    Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufmann J, Bonnem EM, Fefer A.

    J Clin Oncol. 1989 May;7(5):629-37.PMID: 2651578 [PubMed - indexed for MEDLINE]Related articles

    6.

    Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study.

    Ganser A, Lindemann A, Ottmann OG, Seipelt G, Hess U, Geissler G, Kanz L, Frisch J, Schulz G, Herrmann F, et al.

    Blood. 1992 May 15;79(10):2583-91.PMID: 1586711 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.

    Ganser A, Völkers B, Greher J, Ottmann OG, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D.

    Blood. 1989 Jan;73(1):31-7.PMID: 2642714 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

    Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E 3rd, Schnipper LE.

    N Engl J Med. 1988 Sep 8;319(10):593-8.PMID: 3045544 [PubMed - indexed for MEDLINE]Related articles

    9.

    The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia.

    Ganser A, Ottmann OG, Erdmann H, Schulz G, Hoelzer D.

    Ann Intern Med. 1989 Dec 1;111(11):887-92.PMID: 2683920 [PubMed - indexed for MEDLINE]Related articles

    10.

    Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor.

    Lieschke GJ, Cebon J, Morstyn G.

    Blood. 1989 Dec;74(8):2634-43.PMID: 2684297 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.

    Steward WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern G, Crowther D.

    Br J Cancer. 1989 Jan;59(1):142-5.PMID: 2667607 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia.

    Guinan EC, Sieff CA, Oette DH, Nathan DG.

    Blood. 1990 Sep 15;76(6):1077-82.PMID: 2205306 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.

    Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC Jr, Gilbert CJ, Oette DH.

    N Engl J Med. 1988 Apr 7;318(14):869-76.PMID: 3281007 [PubMed - indexed for MEDLINE]Related articles

    14.

    Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.

    Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr, Piñeiro LA, Cooper BW, DiCesare J, Campion M, et al.

    Blood. 1994 Oct 1;84(7):2151-7.PMID: 7919329 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.

    Hovgaard DJ, Nissen NI.

    J Clin Oncol. 1992 Mar;10(3):390-7.PMID: 1740678 [PubMed - indexed for MEDLINE]Related articles

    16.

    Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial.

    Ganser A, Völkers B, Greher J, Walther F, Hoelzer D.

    Onkologie. 1988 Feb;11(1):53-5.PMID: 3283627 [PubMed - indexed for MEDLINE]Related articles

    17.

    Phase I study of subcutaneously-administered bacterially-synthesised recombinant human granulocyte-macrophage colony-stimulating factor.

    Schwartz GK, Collins JJ, Galazka A, Nessi PA, Lehrer D, Baldwin Y, Mandeli J, Holland JF.

    Eur J Cancer. 1992;28(2-3):470-3.PMID: 1591065 [PubMed - indexed for MEDLINE]Related articles

    18.

    Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.

    Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, Bonadonna G.

    J Clin Oncol. 1990 May;8(5):768-78.PMID: 2185337 [PubMed - indexed for MEDLINE]Related articles

    19.

    Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.

    Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R.

    Behring Inst Mitt. 1988 Aug;(83):107-18.PMID: 2467645 [PubMed - indexed for MEDLINE]Related articles

    20.

    Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia.

    Welte K, Zeidler C, Reiter A, Müller W, Odenwald E, Souza L, Riehm H.

    Blood. 1990 Mar 1;75(5):1056-63.PMID: 1689595 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity